Keywords : Drug, antidepressant, Escitalopram, Lexapro, Trazodone, Venlafaxine, Selective serotonin reuptake inhibitor, Pristiq, Pipamperone, Remeron
About This Report Patents for the current industry -leading depression brands are due to expire in the major industry s between 2012 and 2015, by which time competition in the industry will be at its fiercest. In order to flourish in this harsh environment, new antidepressants must be sufficiently differentiated from conventional monoamine neurotransmitter reuptake inhibitors. What's Included in This Report? ...
More »
Search ReportLinker
The Largest Collection of Market Research Reports
» 1.2 Million Industry Reports
» 450,000 Company Profiles
» 850,000 Market Briefings
» 40,000 Country Guides
From +200,000 authoritative sources
About This Report
Patents for the current industry -leading depression brands are due to expire in the major industry s between 2012 and 2015, by which time competition in the industry will be at its fiercest. In order to flourish in this harsh environment, new antidepressants must be sufficiently differentiated from conventional monoamine neurotransmitter reuptake inhibitors.
What's Included in This Report?
* Understand Datamonitor’s independent appraisal of industry ed brands and key pipeline agents indicated for treating depression.
* Illustrate how pipeline and industry ed drugs compare to one another in terms of clinical and commercial attributes.
* Review important clinical developments for key pipeline agents with analysis of the latest clinical trial data.
* Understand how industry ed brands are positioned in the depression treatment algorithm and how they are perceived by psychiatrists.
* Determine to what extent future therapies satisfy the main clinical unmet needs in depression treatment.
Key Market Facts
Datamonitor’s physician survey reveals that psychiatrists perceive Forest’s and Lundbeck’s selective serotonin reuptake inhibitor Lexapro (escitalopram) to be the leading depression treatment, with a superior efficacy and tolerability profile to other antidepressant brands.
Valdoxan (agomelatine; Servier/Novartis) and several pipeline antidepressants are poised to usurp Lexapro, following its loss of industry exclusivity, and become the most attractive depression brands.
Forest’s Viibryd (vilazodone) has the hallmarks of a new blockbuster – a novel mode of action, favorable tolerability, and the industry ing prowess of Forest. Viibryd will be well received due to its good tolerability, although commercial success comparable to Lexapro will be unattainable as more innovative competitor drugs near the US industry .
Why Should You Buy This Report?
* What is the gold-standard drug for depression?
* How are industry ed brands positioned in the depression treatment algorithm?
* Which are the most likely drugs to emerge from the pipeline and how will they impact the way depression is treated?
* What are the comparative strengths and weaknesses of the key depression brands and pipeline candidates?
Drug And Medication Industry
Summary
Strategic scoping and focus
Datamonitor key findings
Related reports
OVERVIEW
Catalyst
Summary
MARKET DEFINITION AND OVERVIEW
Product overview
MARKETED PRODUCT PROFILES
Lexapro (escitalopram; Forest/Lundbeck)
Drug presentation
Drug pipeline analysis
SWOT analysis
Portfolio
Physicians' perceptions of Lexapro
Clinical and commercial attractiveness
Effexor XR (venlafaxine extended release; Pfizer)
Drug presentation
Drug pipeline analysis
SWOT analysis
Portfolio
Clinical and commercial attractiveness
Pristiq (desvenlafaxine; Pfizer)
Drug presentation
Drug pipeline analysis
SWOT analysis
Portfolio
Physicians' perceptions of Pristiq
Clinical and commercial attractiveness
Cymbalta (duloxetine; Eli Lilly/Shionogi)
Drug presentation
Drug pipeline analysis
SWOT analysis
Portfolio
Physicians' perceptions of Cymbalta
Clinical and commercial attractiveness
Valdoxan (agomelatine; Servier/Novartis)
Drug presentation
Drug pipeline analysis
SWOT analysis
Portfolio
Physicians' perceptions of Valdoxan
Clinical and commercial attractiveness
Abilify (aripiprazole; Bristol-Myers Squibb/Otsuka)
Drug presentation
Drug pipeline analysis
SWOT analysis
Portfolio
Physicians' perceptions of Abilify
Clinical and commercial attractiveness
Seroquel XR (quetiapine extended release; AstraZeneca)
Drug presentation
Drug pipeline analysis
SWOT analysis
Portfolio
Physicians' perceptions of Seroquel XR
Clinical and commercial attractiveness
Oleptro (trazodone extended release; Labopharm)
Drug presentation
Drug pipeline analysis
SWOT analysis
Portfolio
Clinical and commercial attractiveness
Other industry ed drugs for depression
Remeron (mirtazapine; Merck & Co./Meiji Seika)
PIPELINE PRODUCT PROFILES
Viibryd (vilazodone; Forest)
Drug presentation
Drug pipeline analysis
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
Lu AA21004 (Lundbeck/Takeda)
Drug presentation
Drug pipeline analysis
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
TC-5214 (Targacept/AstraZeneca)
Drug presentation
Drug pipeline analysis
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
Levomilnacipran (F2695; Forest/Pierre Fabre)
Drug presentation
Drug pipeline analysis
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
Edivoxetine (LY2216684; Eli Lilly)
Drug presentation
Drug pipeline analysis
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
Vyvanse (lisdexamfetamine; Shire)
Drug presentation
Drug pipeline analysis
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
Other drugs in development for depression
CPI-300 (bupropion; IntelGenx)
AZD6765 (AstraZeneca)
BCI-224 (sabcomeline; BrainCells)
BCI-540 (coluracetam; BrainCells/Mitsubishi Tanabe)
BCI-952 (melatonin and buspirone; Brain Cells)
BMS-820836 (Bristol-Myers Squibb/AMRI)
Cariprazine (RGH-118; Forest/Gedeon Richter/Mitsubishi Tanabe)
Cimicoxib (UR-8880; Affectis Pharmaceuticals/Palau Pharma)
CP-601,927 (Pfizer)
EB-1010 (Euthymics Bioscience)
GLYX-13 (Naurex)
JNJ-26489112 (Johnson & Johnson)
Lu AA24530 (Lundbeck/Takeda)
OPC-34712 (Otsuka)
Orvepitant (GSK823296; GlaxoSmithKline)
PNB-01 (pipamperone and citalopram; PharmaNeuroBoost)
RG7090 (Roche)
SA4503 (cutamesine; M’s Science)
Serdaxin (clavulanic acid; Rexahn Pharmaceuticals)
SSR125543 (Sanofi)
Tasimelteon (VEC-162; Vanda Pharmaceuticals)
TriRima (CX157; CeNeRx/Krenitsky Pharmaceuticals)
BIBLIOGRAPHY
Journal papers
Websites
Datamonitor reports
APPENDIX A – SURVEY INFORMATION
Physician research methodology
Physician sample breakdown
The survey questionnaire
Introduction
Section one: diagnosis and patient sector ation
Section two: treatment of major depressive disorder
Section three: product profiles
Demographics
APPENDIX B
PharmaVitae Explorer database
Contributing experts
Conferences attended
Report methodology
